DHR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Danaher Corp (DHR) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock has shown a recent negative price trend and lacks strong positive catalysts or trading signals. While the company's financial performance is solid, the technical indicators and options sentiment suggest caution. Analysts maintain an overall positive outlook, but recent price target reductions indicate some risk in the short term. Holding off for now is a prudent approach.
The stock's MACD is above 0 and positively contracting, indicating a neutral to slightly bullish momentum. RSI is neutral at 49.781, and moving averages are converging, showing no clear trend. The stock is trading near a key support level (S1: 189.378), but the overall technical setup does not strongly favor a buy. The stock trend analysis suggests a potential decline of -2.82% in the next week and -9.89% in the next month.
The company's Q4 2025 financials show solid growth with revenue up 4.59% YoY, net income up 10.22% YoY, and EPS up 12.75% YoY. Additionally, the MeMed BV assay has potential to drive healthcare cost savings and improve clinical decision-making, which could benefit Danaher's life sciences segment.
The stock trend analysis predicts further declines in the short term.
Danaher Corp reported strong Q4 2025 financials with revenue of $6.84 billion (up 4.59% YoY), net income of $1.197 billion (up 10.22% YoY), and EPS of $1.68 (up 12.75% YoY). However, gross margin declined to 58.2%, down -2.18% YoY.
Analysts maintain an overall positive outlook with multiple Outperform and Buy ratings. However, recent price target reductions (e.g., Barclays to $230 from $250, Evercore ISI to $225 from $254) reflect cautious sentiment due to risks in the life sciences and diagnostics tools sector. Analysts believe in the sector's recovery potential but acknowledge near-term challenges.
